Ammirata Giorgia, Arigoni Maddalena, Licastro Danilo, Caviglia Gian Paolo, Disabato Michela, Zubair Ghania, Bezzio Cristina, Saibeni Simone, De Nicolò Amedeo, Cusato Jessica, Palermiti Alice, Manca Alessandra, Tolosano Emanuela, Cozzini Stefano, Mancini Marcello, Altruda Fiorella, D'Avolio Antonio, Ribaldone Davide Giuseppe, Ala Ugo, Fagoonee Sharmila
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre "Guido Tarone", University of Turin, 10126 Turin, Italy.
AREA Science Park, Padriciano, 34149 Trieste, Italy.
Antioxidants (Basel). 2024 Aug 28;13(9):1047. doi: 10.3390/antiox13091047.
The relationship between serum 25-hydroxyvitamin D (25(OH)D) levels, genomic response to vitamin D (Vit.D), and positivity to SARS-CoV-2 remains understudied. In this pilot study, during the follow-up of patients with Inflammatory Bowel Disease (IBD) and COVID-19, we investigated this issue by analyzing the molecular contents of serum extracellular vesicles (EVs) from six groups of IBD patients (n = 32), classified according to anti-SARS-CoV-2 status, 25(OH)D level, and Vit.D supplementation, by small RNA-seq. This analysis revealed differentially expressed miRNAs, PIWI-RNA, transfer RNA, small nucleolar RNAs, and protein-coding RNAs in the EVs obtained from these cohorts of IBD patients. Experimental validation evidenced a statistically significant increase in miR30d-5p, miR150-5p, Let-7f-5p, and Let-7a-5p in the anti-SARS-CoV-2-positive and low 25(OH)D and Vit.D supplemented groups with respect to the non-Vit.D supplemented group, indicating their responsiveness to Vit.D treatment. Bioinformatics analysis highlighted the regulation of these validated miRNAs by oxidative stress and inflammation, hallmarks of IBD and COVID-19. Our study reports an unprecedented panel of circulating EV-enclosed inflammation- and oxidative stress-related miRNAs, the potentiality of which, as biomarkers for Vit.D responsivity in IBD patients, needs to be explored in future studies on larger cohorts in order to allow clinicians to optimize current treatment strategies upon viral infection.
血清25-羟基维生素D(25(OH)D)水平、维生素D(Vit.D)的基因组反应与新型冠状病毒(SARS-CoV-2)阳性之间的关系仍未得到充分研究。在这项初步研究中,我们在对炎症性肠病(IBD)合并COVID-19患者的随访期间,通过小RNA测序分析了六组IBD患者(n = 32)血清细胞外囊泡(EVs)的分子内容物,这些患者根据抗SARS-CoV-2状态、25(OH)D水平和Vit.D补充情况进行分类,以此来研究这一问题。该分析揭示了在这些IBD患者队列获得的EVs中,微小RNA(miRNAs)、PIWI相互作用RNA、转运RNA、小核仁RNA和蛋白质编码RNA存在差异表达。实验验证表明,在抗SARS-CoV-2阳性、低25(OH)D且补充Vit.D的组中,与未补充Vit.D的组相比,miR30d-5p、miR150-5p、Let-7f-5p和Let-7a-5p有统计学意义的增加,表明它们对Vit.D治疗有反应。生物信息学分析突出了氧化应激和炎症对这些经验证的miRNAs的调节作用,而氧化应激和炎症是IBD和COVID-19的特征。我们的研究报告了一组前所未有的循环EV包裹的与炎症和氧化应激相关的miRNAs,其作为IBD患者Vit.D反应性生物标志物的潜力,需要在未来对更大队列的研究中进行探索,以便临床医生在病毒感染时优化当前的治疗策略。